• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>IMS Health

IMS Health

RX Safes Inc RXSF

Last Price$0.02Day Change (%)32.74%
Open Price$0.01Day Change ($)0.00
Day Range0.01–0.0252-Week Range0.01–1.00

As of Fri 4/24/2015 4:55:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation

    Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation

  2. IMS Health's Social Media Analytics Solution Named a Leader by IDC MarketScape

    IMS Health's Social Media Analytics Solution Named a Leader by IDC MarketScape

  3. IMS Health Study: Reimbursement Approaches Based on Cost-Per-Quality-Adjusted-Life-Year Measures Rather Than Drug Effectiveness May Limit Access to Innovative Cancer Treatments

    IMS Health Study: Reimbursement Approaches Based on Cost-Per-Quality-Adjusted-Life-Year Measures Rather Than Drug Effectiveness May Limit Access to Innovative Cancer Treatments

  4. Meet Pharma's Newest Movers and Shakers, Driving M&A

    Meet Pharma's Newest Movers and Shakers, Driving M&A

  5. Meet Pharma's Newest Movers and Shakers, Driving M&A

    Meet Pharma's Newest Movers and Shakers, Driving M&A

  6. Perrigo Announces The Launch Of A Generic Version Of Kenalog® Nasal Spray

    Perrigo Announces The Launch Of A Generic Version Of Kenalog® Nasal Spray

  7. Mylan Launches First Generic Version of Generess Fe®

    Mylan Launches First Generic Version of Generess Fe®

  8. Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD

    Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD

  9. Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015

    Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015

  10. Our Take on the Second Quarter

    Despite the Fed taper, a U.S. economy struggling to shake off the winter blues, and a slowing China, stocks continued their remarkable winning streak from April through June.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.